|
Q2 FY2027
As of Aug 31, 2026
|
Q1 FY2027
As of May 31, 2026
|
Q4 FY2026
As of Feb 28, 2026
|
Q3 FY2026
As of Nov 30, 2025
|
Q2 FY2026
As of Aug 31, 2025
|
Q1 FY2026
As of May 31, 2025
|
Q4 FY2025
As of Feb 28, 2025
|
Q3 FY2025
As of Nov 30, 2024
|
Q2 FY2025
As of Aug 31, 2024
|
Q1 FY2025
As of May 31, 2024
|
Q4 FY2024
As of Feb 29, 2024
|
Q3 FY2024
As of Nov 30, 2023
|
Q2 FY2024
As of Aug 31, 2023
|
Q1 FY2024
As of May 31, 2023
|
Q4 FY2023
As of Feb 28, 2023
|
Q3 FY2023
As of Nov 30, 2022
|
Q2 FY2023
As of Aug 31, 2022
|
Q1 FY2023
As of May 31, 2022
|
Q4 FY2022
As of Feb 28, 2022
|
Q3 FY2022
As of Nov 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable - related parties | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued officer compensation | ||||||||||||||||||||
| Loan payable - related parties | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Commitment and Contingencies | ||||||||||||||||||||
| Stockholders' Deficit | ||||||||||||||||||||
| Common stock, $0.001 par value per share 75,000,000 shares authorized; 199,867 and 199,867 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' Deficit | ||||||||||||||||||||
Loading...
